4-Amino-6-chloropyrimidine-5-carboximidoyl bromide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-Amino-6-chloropyrimidine-5-carboximidoyl bromide
• 英文别名: 4-amino-6-chloropyrimidine-5-carboximidoyl bromide
• 化学式: C₅H₄BrClN₄
• 分子量: 235.47
• InChiKey: MQFLKQOXOKLMAP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：PHARMACYCLICS LLC

  公开号：WO2016004272A1

  公开（公告）日：2016-01-07

  Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了抑制布鲁顿酪氨酸激酶（Btk）的化合物。还描述了Btk的不可逆抑制剂。此外，还描述了Btk的可逆抑制剂。还披露了包括这些化合物的药物组合物。披露了使用Btk抑制剂的方法，单独或与其他治疗剂联合治疗自身免疫疾病或症状、异源免疫疾病或症状、癌症（包括淋巴瘤）和炎症性疾病或症状。
• [EN] SUBSTITUTED PYRAZOLOPYRIMIDINYLAMINO-INDAZOLES<br/>[FR] PYRAZOLOPYRIMIDINYLAMINOINDAZOLES SUBSTITUÉS
  申请人：BAYER PHARMA AG

  公开号：WO2014118226A1

  公开（公告）日：2014-08-07

  The present invention relates to substituted pyrazolopyrimidinylamino-indazole compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一种一般式I所述的取代的吡唑吡咯啉基氨基吲哚化合物，以及制备该化合物的方法，用于制备该化合物的中间体化合物，含有该化合物的药物组合物和组合物，以及使用该化合物制备治疗或预防疾病的药物组合物，特别是治疗或预防增生和/或血管生成障碍的药物组合物，作为唯一的药物或与其他活性成分组合使用。
• NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3848054A1

  公开（公告）日：2021-07-14

  Desired is development of novel CDN derivatives having STING agonist activity; and a therapeutic agents and/or therapeutic methods using the novel CDN derivatives for diseases associated with STING agonist activity. Further desired is development of a therapeutic agents and/or therapeutic methods capable of delivering the novel CDN derivatives specifically to targeted cells and organs for diseases associated with STING agonist activity. The present invention provides novel CDN derivatives having potent STING agonist activity, and antibody-CDN derivative conjugates including the novel CDN derivatives.

  希望开发出具有 STING 激动剂活性的新型 CDN 衍生物；以及使用新型 CDN 衍生物治疗与 STING 激动剂活性相关疾病的治疗剂和/或治疗方法。还希望开发一种治疗剂和/或治疗方法，能够将新型 CDN 衍生物特异性地输送到靶细胞和器官，以治疗与 STING 激动剂活性相关的疾病。本发明提供了具有强效 STING 激动剂活性的新型 CDN 衍生物，以及包括新型 CDN 衍生物的抗体-CDN 衍生物共轭物。
• SUBSTITUTED PYRAZOLOPYRIMIDINYLAMINO-INDAZOLES
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2951175B1

  公开（公告）日：2017-10-04